NeuroOne Collaborates with University of Minnesota to Advance Brain Drug Delivery Platform for Epilepsy

NeuroOne Medical Technologies Corporation announced a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating next-generation epilepsy therapies using the company's sEEG-based platform. The program tests novel therapeutics delivered locally into specific brain regions involved in sustaining seizures with the goal of improving clinical efficacy and lowering systemic toxicity and off-target effects. The collaboration is expected to begin in large animal models and, if primary objectives are met, progress to human studies shortly thereafter.

Sandipan Pati, MD, Professor and Epilepsy Division Director, leads the program as an academic, dual board-certified epileptologist, and neurophysiologist at the forefront of innovation in epilepsy care and research. Pati stated that localized intracerebral delivery of therapeutics represents an important emerging direction for improving precision in epilepsy treatment while minimizing systemic side effects. In clinical practice, FDA-cleared intracranial electrodes are used for recording brain activity and performing therapeutic interventions such as stimulation and ablation. Current research focuses on preclinical studies evaluating the feasibility, safety, and physiological effects of intracerebral drug infusion using minimally invasive intracranial platforms, including ultra-thin electrode-based systems designed to reduce tissue disruption.

These pre-clinical studies aim to better understand how targeted delivery influences seizure networks and brain-body interactions. If successful, this approach may help inform future translational efforts toward a human study to develop more precise and individualized therapies for patients with epilepsy. Pati serves as Director of the University of Minnesota Physicians MINCEP Epilepsy Care Program and epileptologist at M Health Fairview, bringing extensive clinical and research expertise to the collaboration.

Dave Rosa, President and CEO of NeuroOne, emphasized that the University of Minnesota is at the forefront of next-generation epilepsy research. As NeuroOne continues advancing its preclinical drug delivery platform toward commercial readiness, this collaboration will support development of a first-in-human study utilizing the technology for intracerebral treatment of epileptic seizures. If successful, this approach could redefine seizure care and establish a new era of precision brain-directed therapy. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System.

These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions. The company is engaged in research and development for drug delivery and spinal cord stimulation programs. For more information about NeuroOne's technology platform and research initiatives, visit https://nmtc1.com. The forward-looking statements in the announcement highlight the potential of this collaboration while acknowledging risks related to clinical trials, regulatory requirements, and market acceptance of the technology.